However, HIV advocates told the news outlet they are concerned about the drug’s high cost and potential disparities that could exacerbate racial inequalities in HIV prevention.
Black and Latino gay and bisexual men, who face the highest HIV rates, have historically struggled with low adherence to daily oral prEP, such as Truvada and Descovy.
Despite lenacapavir’s potential, the drug is priced at $3,450 per month, posing a potential barrier for patients. The drug’s manufacturer, Gilead Sciences, is having discussions about pricing, but the cost of widespread domestic access with the medication remains uncertain, according to the report.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
